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Prognostic signiﬁcance of DNA repair proteins MLH1, MSH2 and MGMT expression in
non-small-cell lung cancer and precursor lesions
Aims: To investigate the role of DNA repair proteins
and their prognostic signiﬁcance in non-small-cell lung
cancer (NSCLC).
Methods and results: A retrospective analysis of 108
cases of stage I–II NSCLC was undertaken. Immuno-
histochemical expression of DNA repair proteins MLH1,
MSH2 and MGMT was assessed using tissue micro-
arrays of parafﬁn-embedded samples of invasive carcin-
oma and precursor lesions. Results were analysed in
relation to clinicopathological parameters and patient
survival. Reduced expression of MLH1 was found in
58.5% of tumours and occurred less frequently in
poorly differentiated tumours (P = 0.044) and large
cell carcinomas (P = 0.004). MSH2 and MGMT expres-
sion was reduced in 18.1% and 77.8% of cases,
respectively. There was an inverse relationship be-
tween MLH1 and MSH2 expression (P = 0.012). Nor-
mal expression of MLH1, MSH2 and MGMT was found
in all cases of squamous metaplasia and squamous
dysplasia. Only a single case of carcinoma in situ
(12.5%) showed reduced MLH1, none showed reduced
MSH2 and 25% showed reduced MGMT. Survival
analyses showed no prognostic signiﬁcance based on
expression of MLH1 (P = 0.92), MSH2 (P = 0.78) or
MGMT (P = 0.57).
Conclusions: Reduction in expression of DNA repair
proteins MLH1, MSH2 and MGMT is relatively common
in NSCLC, appears to be a late event in the development
of invasive malignancy and does not inﬂuence survival
in this patient cohort.
Keywords: DNA mismatch repair proteins, immunohistochemistry, MGMT, MLH1, MSH2, non-small-cell lung
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The role of DNA mismatch repair (MMR) proteins in
sporadic and hereditary colorectal carcinoma has been
extensively investigated,
1 but the role of these proteins
in the molecular pathogenesis of non-small-cell lung
cancer (NSCLC) is poorly understood. Alterations in
DNA produced during replication and recombination
are repaired by the MMR system in an effort to maintain
genomic stability, and tumours lacking MMR function
exhibit a mutator phenotype.
2 In addition, the cytotoxic
effects of a number of alkylating agents used in the
treatment of cancer are dependent on a functional MMR
system.
2 Hereditary non-polyposis colorectal cancer
(HNPCC ⁄ Lynch syndrome) is an autosomal dominant
condition, which comprises 2–5% of all colorectal
cancers. It results from germ-line mutations in MMR
genes, with alterations of hMLH1 and hMSH2 account-
ing for the vast majority of cases.
1 This syndrome is
characterized by genetic instability and the propensity
to develop a number of neoplasms, particularly colo-
rectal cancer and, to a lesser extent, malignancies of the
endometrium, stomach, pancreas, ureters, ovaries,
brain and skin.
3 Pulmonary neoplasms are not a
characteristic feature of this syndrome, suggesting that
defective MMR gene function may not play a major role
in the pathogenesis of NSCLC. Interestingly, alterations
in expression of MMR proteins MLH1 and MSH2 have
been reported in a variable proportion of NSCLC
ranging from 18%
4 to 61%,
5 but no studies have
investigated the role of reduced protein expression in
precursor lesions of NSCLC and very few have investi-
gated their potential prognostic signiﬁcance in invasive
carcinomas.
Methyl guanine DNA methyltransferase (MGMT) is a
DNA repair enzyme involved in removal of abnormal
adducts from the O
6 position of guanine, providing
protection from mutagenic agents and conferring resis-
tance to alkylating chemotherapeutic drugs.
2 MGMT
expression is thought to be induced by a number of toxic
agents, including cigarette smoke.
6 Promoter region
methylation resulting in reduced expression of MGMT
occurs commonly in a variety of tumours such as
colorectal cancer and melanoma
7,8 and has been
reported as an unfavourable prognostic factor in
NSCLC.
9 However, very few studies have investigated
the role of altered MGMT protein expression in NSCLC.
In this study, expression of DNA repair proteins
MLH1, MSH2 and MGMT were investigated in early-
stage NSCLC and precursor lesions using tissue micro-
arrays (TMAs) and the results have been correlated
with clinicopathological parameters and patient
survival.
Materials and methods
patient cohort
Tumour samples and clinical follow-up data were
obtained from a cohort of 108 stage I–II NSCLC
patients treated at the Royal Prince Alfred Hospital,
Sydney, Australia between 1997 and 1999. The cohort
included 70 (64.8%) men and 38 women (35.2%) with
a median age at diagnosis of 67 years (range 41–
81 years) and median survival time of 72 months
(range 3.3–97.5 months), excluding patients with
survival <60 days. Histological tumour subtypes were
assessed using the World Health Organization classiﬁ-
cation,
10 and there were 48 (44.4%) adenocarcinomas
(ADCs) [including seven bronchioloalveolar carcin-
omas (BACs)], 19 (17.6%) large cell carcinomas (LCCs),
40 (37.0%) squamous cell carcinomas (SCCs) and one
(0.9%) mixed adenosquamous carcinoma. For survival
analyses, invasive ADCs and (non-invasive) BACs
were assessed both separately and as a single group.
Tumours were staged using the American Joint Com-
mittee on Cancer Tumor-Node-Metastasis classiﬁca-
tion
11 and consisted of 88 (81.5%) stage I and 20
(18.5%) stage II tumours. Regional lymph node
metastases were available from nine patients. Precur-
sor lesions were also assessed when available, and there
were up to 13 cases of bronchial squamous epithelial
metaplasia, two with low-grade dysplasia, and eight
cases of bronchial SCC in situ; however, there was
insufﬁcient material for adequate assessment of all of
these cases with all three markers. Follow-up informa-
tion of at least 5 years was available for this study.
tumour samples
TMAs were constructed using three to four donor
cores of tumour, 1 mm in diameter, from appropriate
areas in formalin-ﬁxed parafﬁn-embedded tissue
blocks. These tissue cores were arrayed into a recipient
parafﬁn block using a tissue arraying instrument
(Beecher Instruments, Silver Springs, MD, USA). Serial
sections were cut from the TMA blocks at 4 lm
thickness and mounted on glass slides. The use of
TMAs to investigate immunohistochemical expression
of MLH1 and MSH2 as opposed to whole sections of
tumours has been validated in a study of colorectal
carcinomas.
12
immunohistochemistry
Sectionsweredeparafﬁnizedwithxyleneandrehydrated
through graded alcohols to water. Immunohisto-
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MLH1 and MSH2 genes was undertaken using the
following antibodies. MLH1 (clone G168-15; BD
Pharmingen, San Diego, CA, USA; diluted 1:100),
MSH2 (clone FE11; Oncogene, San Diego, CA, USA;
diluted 1:1000) and MGMT (clone MT23.2; Zymed,
Carlsbad, CA, USA; diluted 1:600). Immunohistochem-
istry was performed using Goat Anti-Mouse IgG,
Polymer-Horseradish Peroxidase IHC ampliﬁcation
reagent (Chemicon, Temecula, CA, USA) as the detec-
tion system and 3,3¢-diaminobenzidine as the substrate
chromogen (ICN Biomedicals, Aurora, OH, USA). Heat-
induced antigen retrieval was performed by heating in
a pressure cooker (Decloaking Chamber; Biocare Med-
ical, Concord, CA, USA) in preheated citrate buffer
(10 mmol ⁄ l, pH 6.0) for 5 min. In some cases, the
tissue sections were microwave treated in preheated
ethylenediamine tetraaceticacid buffer for 20–40 min.
All immunohistochemistry was performed on a
Sequenza rack with Coverplate (ThermoShandon,
Pittsburgh, PA, USA). The slides were treated with
1% goat serum and then incubated with primary
antibody overnight at room temperature. Upon com-
pletion of a Tris buffer wash, the slides were incu-
bated with enzyme-conjugated polymer with goat
antimouse IgG antibody for 30 min at room temper-
ature and then washed in buffer. After reaction with
diaminobenzidene ⁄ hydrogen peroxide for 5 min, slides
were rinsed in distilled water and immersed in 1%
copper sulphate solution for 1 min. After washing, the
sections were counterstained in Gill’s Haematoxylin 2
(Australian Biostain, Traralgon, Australia) solution for
30 s, followed by blueing solution for 15 s.
The positive controls were matched samples of
normal bronchial mucosa and peripheral lung paren-
chyma incorporated into the tissue arrays. Samples of
normal bronchial mucosa showed positive staining for
MMR proteins in an average of 95–100% of cells in all
cases except for two cases stained with MLH1, which
were excluded from the analysis. Samples from normal
spleen were also incorporated into the arrays to use as
both external positive controls and also as reference
points within the arrays. Nuclear expression of MLH1
was also seen in all splenic samples, but the reactivity
was not scored. A negative control slide was incubated
with non-immune serum instead of the primary
antibody.
scoring
Two pathologists (W.A.C. and C.C.) independently
scored each case without knowledge of the patient’s
clinical details and an average of the two scores
obtained was used. Immunohistochemical expression
of MLH1 was scored semiquantitatively by multiplying
the percentage of cells showing nuclear expression and
the intensity of immunoreactivity using a three-tier
grading system (1 = weak, 2 = moderate and 3 =
strong). An average score was obtained from the
multiple samples of each case and reduced protein
expression was taken as cases with a score of <200.
Where markedly discrepant, the case was reviewed
before deciding on an appropriate score. There was
good correlation between the scores obtained from
each pathologist (MLH1 correlation coefﬁcient R =
0.94, P < 0.01; MSH2 R = 0.79, P < 0.001 and
MGMT R = 0.96, P < 0.001).
statistical analyses
The Pearson v
2 test and Fisher’s exact test (two-sided)
were used to compare associations between protein
expression and various clinicopathological character-
istics. The Kaplan–Meier log rank and Cox propor-
tional regression model were used for survival
analyses. SPSS statistical software package version
13.0 was used for all analyses (SPSS Inc., Chicago, IL,
USA). P-values of <0.05 were regarded as statistically
signiﬁcant.
Results
mmr protein expression
Nuclear expression of MLH1 was seen extensively in
normal tissues, but was reduced in 62 out of the 106
cases of NSCLC (58.5%) (Figure 1). In SCC, MLH1
expression was reduced in 27 ⁄ 39 (69.2%), in LCCs
5 ⁄ 18 (27.8%) and in ADCs 30 ⁄ 48 (62.5%),
including 5 ⁄ 7 (71.4%) BACs. Of eight cases of
bronchial epithelial squamous carcinoma in situ, only
one case (12.5%) showed reduced MLH1 expression.
Thirteen cases of bronchial epithelial squamous
metaplasia were assessed and none had reduced
expression of MLH1, including two cases with low-
grade dysplasia. Of nine cases with lymph node
metastases, only two (22.2%) showed reduced MLH1
expression.
There was reduced MSH2 expression in 19 of 105
cases (18.1%) (Figure 2). In different histological sub-
types, MSH2 was reduced in 4 ⁄ 39 SCCs (10.3%), 3 ⁄ 16
(18.8%) LCCs and 11 of 48 (22.9%) ADCs, including
2 ⁄ 7 (28.6%) BACs. MSH2 was not reduced in any of
the seven cases of bronchial epithelial squamous
carcinoma in situ or any of the 11 cases of squamous
metaplasia with or without dysplasia in bronchial
DNA repair proteins in lung cancer 615
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metastases, with none showing reduced MSH2
expression.
Reduced MGMT scores were seen in 84 of 108 cases
(77.8%) of NSCLC (Figure 3). In SCC, 32 (80%)
showed reduced expression of MGMT, LCC 13
AB
C
E
D
Figure 1. Immunohistochemistry for MLH1. Strong expression of
MLH1 is seen in (A) normal bronchial epithelium, (B) bronchial
epithelium with squamous metaplasia, (C) bronchial epithelium
with carcinoma in situ (most cases) and most invasive squamous
cell carcinomas (SCCs) (D). Some cases of invasive SCC show
reduced expression of MLH1 (E).
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bronchial epithelial squamous carcinoma in situ, there
was reduced MGMT expression in two (25%) cases.
Samples of bronchial epithelial squamous metaplasia
did not show any reduction in MGMT reactivity in the
eight cases (0%) without dysplasia or the two cases
A
B
C
Figure 3. Immunohistochemistry of methyl guanine DNA methyl-
transferase (MGMT) in (A) normal bronchial epithelium, (B) large cell
carcinoma with normal expression of MGMT, and (C) large cell
carcinoma with reduced expression of MGMT.
A
B
C
Figure 2. Immunohistochemistry of MSH2 in (A) normal bronchial
epithelium, (B) adenocarcinoma with normal expression of MSH2,
and (C) adenocarcinoma with reduced expression of MSH2.
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MLH1 expression MSH2 expression MGMT expression
Normal Reduced v
2, P-value Normal Reduced v
2, P-value Normal Reduced v
2, P-value
Tumour type 0.028* 0.29 0.64
ADC 16 24 0.81 37 11 0.24 10 37 0.84
BAC 2 5 0.47 5 2 0.46 2 5 0.68
SCC 12 27 0.087 35 4 0.11 8 32 0.67
LCC 13 5 0.004* 13 3 0.94 6 13 0.28
Mixed 1 1 † 1 1 † 0 2 †
Differentiation 0.11 0.84 0.61
Well 2 6 0.32 6 2 0.60 3 6 0.40
Mod 20 37 0.15 50 10 0.66 11 46 0.44
Poor 22 19 0.044* 30 7 0.87 10 32 0.75
Size, mm 0.79 0.39 0.33
£30 23 34 45 12 15 43
>30 21 28 41 7 9 41
Sex 0.17 0.95 0.24
Male 32 37 55 12 18 52
Female 12 25 31 7 6 32
Age, years 0.74 0.87 0.61
<67 22 33 39 9 10 40
‡67 22 29 47 20 14 44
Stage 0.76 0.84 0.47
1A 11 19 0.52 24 7 0.44 9 22 0.28
1B 23 33 0.92 46 8 0.37 10 47 0.22
2A 3 2 0.39 4 1 0.91 2 3 0.33
2B 7 8 0.66 12 3 0.84 3 12 0.82
BVI 0.81 0.14 0.28
Absent 41 57 81 16 21 79
Present 3 5 5 3 3 5
LVI 0.32 0.60 0.84
Absent 42 56 80 17 22 78
Present 2 6 6 2 2 6
618 W A Cooper et al.
  2008 The Authors. Journal compilation   2008 Blackwell Publishing Ltd, Histopathology, 52, 613–622.(0%) with low-grade dysplasia. Of nine lymph node
metastases, four cases (44.4%) had reduced expression
of MGMT.
correlations between expression of
different proteins
Reduction of either MLH1 or MSH2 was found in
64 ⁄ 104 cases (61.5%) and co-reduction of both MLH1
and MSH2 proteins was found in 16 cases (15.4%).
There was an inverse relationship between expression
of the two proteins that was statistically signiﬁcant
(P = 0.012). Ninety-two of 106 (86.8%) showed
reduction of either MLH1 or MGMT, and 52 cases
(49.1%) showed reduction of both MLH1 and MGMT.
Eighty-three of 105 (79.0%) showed reduction of either
MSH2 and MGMT, and 17 (16.2%) showed reduction
of both of these proteins.
correlations with pathological and
clinical variables
Reduced expression of MLH1 was found to be less
common in LCCs (P = 0.004, Pearson’s v
2; P = 0.007,
Fisher’s exact test two-sided) and poorly differentiated
tumours (P = 0.044, Pearson’s v
2) (Table 1). Other
pathological or patient factors such as gender, age,
tumour size, stage, lymphatic invasion, blood vessel
invasion, perineural invasion and involvement of the
bronchial surgical margin were evenly distributed
between those with and without reduced MLH1
expression. MSH2 and MGMT expression did not
correlate with any of the measured clinicopathological
parameters (Table 1).
mmr protein expression and patient survival
Expression of MMR proteins was compared with overall
patient survival using Kaplan–Meier survival analysis.
No signiﬁcant correlation was found between survival
and expression of MLH1 (P = 0.92), MSH2 (P = 0.78)
or MGMT (P = 0.57) (Figure 4). Tumours that showed
a reduction of either MLH1 or MSH2 (or both) were not
associated with survival (P = 0.83). Similarly, other
combinations of DNA repair protein expression (MLH1
and ⁄ or MGMT reduced, MSH2 and ⁄ or MGMT reduced)
did not correlate with survival (data not shown).
Analysis of survival based on reduced MMR protein
expression using the Kaplan–Meier method was not
signiﬁcant when the data were subanalysed based on
tumour grade, histological type, stage or patient gender
(data not shown). Similarly, using Cox regression
analysis, no signiﬁcant correlation was found between
survival and expression of MLH1 [P = 0.94, hazard
ratio (HR) 0.98, 95% conﬁdence interval (CI) 0.54,
1.76], MSH2 (P = 0.78, HR 0.90, 95% CI 0.44, 1.87)
or MGMT (P = 0.57, HR 0.82, 95% CI 0.41, 1.6).
Discussion
In this study, expression of DNA repair proteins MLH1,
MSH2 and MGMT have been investigated in early-stage
NSCLC and precursor lesions using TMAs. Although
the role of MMR proteins in sporadic and hereditary
colorectal carcinoma has been extensively investi-
gated,
1 the role of these proteins in the molecular
pathogenesis of lung cancer is poorly understood.
Molecular alterations of MMR genes have been found
in a signiﬁcant number of NSCLCs, and promoter
Table 1. (Continued)
MLH1 expression MSH2 expression MGMT expression
Normal Reduced v
2, P-value Normal Reduced v
2, P-value Normal Reduced v
2, P-value
PNI 0.23 0.24 0.45
Absent 44 60 5 18 24 82
Present 0 2 1 1 0 2
Margin 0.39 0.20 0.60
Not involved 40 59 79 19 23 78
Involved 4 3 7 0 1 6
*Statistically signiﬁcant (P < 0.05).
†Too few cases to assess.
ADC, Adenocarcinoma; BAC, bronchioloalveolar carcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma; BVI,
blood vessel invasion; LVI, lymphovascular invasion; PNI, perineural invasion.
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anism of silencing hMLH1 and hMSH2 genes in these
cases.
4,13,14 Some studies have found that loss of
heterozygosity at loci for DNA MMR genes is relatively
frequent in NSCLC,
15,16 whereas others have not been
able to demonstrate hMLH1 promoter methylation.
17
Homozygous deletions or rearrangements have not
been demonstrated in the hMLH1 gene in NSCLC.
15,16
In this study, we have demonstrated that decreased
DNA repair protein expression is relatively common in
NSCLC with MLH1, MSH2 and MGMT reduced in
58.5%, 18.1% and 77.8% of NSCLC cases, respec-
tively. Reduced expression of MLH1 in NSCLC has
been reported at frequencies of 20–61%,
5,18 and in
some studies has been associated with microsatellite
instability.
5,18 Decreased MSH2 expression has been
reported at similar rates ranging from 18%
4 to 58%,
16
and in our study population altered MSH2 was less
frequent than MLH1. The differences between studies
possibly relate to different patient populations and
different criteria being applied to determine reduction of
protein expression.
In a study of 150 cases of NSCLC, Xinarianos et al.
16
have found reduced expression of MLH1 protein in
58.6% of cases, MSH2 in 57.8% and either MLH1 or
MSH2 in 82%. Although we have found reduced
expression of MSH2 in considerably fewer cases, our
results for MLH1 and reduction of either protein were
similar. They did not ﬁnd any correlation between
reduced MLH1 expression and age, gender, tumour
differentiation or TNM T stage, but they did demon-
strate an association with heavy smoking and nodal
metastases in SCC.
16 In contrast, in our study reduced
MLH1 was less common in poorly differentiated
tumours and large cell-type carcinomas. Interestingly,
colorectal carcinomas associated with altered MMR
protein function are associated with a variety of
clinicopathological characteristics, including a propen-
sity to be poorly differentiated.
19,20 As in our study,
Xinarianos et al.
16 have not found hMSH2 expression
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Figure 4. A, Probability of survival according to MLH1 expression
[Kaplan–Meier survival curve, P = 0.92, log rank (Mantel–Cox)].
Reduced MLH1 expression n = 62 (dotted line), normal MLH1
expression n = 44 (solid line). There were 60 censored cases.
B, Probability of survival according to MSH2 expression using
immunohistochemical score (Kaplan–Meier survival, P = 0.78, log
rank test). Reduced MSH2 expression n = 19 (dotted line), normal
MSH21 expression n = 86 (solid line). There were 58 censored cases.
C, Probability of survival according to MGMT expression [(Kaplan–
Meier survival curve, P = 0.57, log rank (Mantel–Cox); P = 0.25,
Breslow; P = 0.36, Tarone–Ware]. Reduced MGMT expression
n = 83 (dotted line), normal MGMT expression n = 24 (solid line).
There were 60 censored cases.
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parameters assessed.
Whereas others have reported no loss of expression
of MMR proteins MLH1, MSH2 or MSH6 in the non-
invasive bronchioloalveolar subtype of ADC,
21 we were
able to demonstrate reduction of MLH1 in 71.4% and
MSH2 in 28.6% of this type of carcinoma. Our results
for this subset of ADC are very similar to our ﬁndings in
all ADCs, suggesting the role of altered DNA MMR
function in both types of tumour, if any, is likely to be
similar. The investigation reported by Aubry et al.
21 did
not include invasive ADCs, criteria used for assessing
immunohistochemical expression were not clearly
deﬁned, and it is possible that methodological differ-
ences could account for the discrepant ﬁndings.
MGMT promoter region methylation has been dem-
onstrated in 7–55% of NSCLC
14,22,23 and is an inde-
pendent predictor of poor prognosis in one study,
9
whereas others have not been able to demonstrate a
signiﬁcant association with survival.
24 Immunohisto-
chemical expression of MGMT has been studied in a
group of 83 stage I–III NSCLC and reduced expres-
sion was found in only 25% of cases,
6 compared
with 77.8% in our study. There was a signiﬁcant
difference in MGMT expression between smokers and
non-smokers (in whom the protein was more fre-
quently reduced)
6 and between ADC and LCC, with
none of the LCCs showing loss of expression, whereas
in our study we did not demonstrate any association
with tumour type and found loss of expression in a
considerable number of LCCs (68.4%). As in our study,
they found no association between MGMT expression
and age, gender, stage or histological tumour type.
The development of pulmonary SCC is known to
occur through a stepwise progression of bronchial
epithelial abnormalities starting from squamous meta-
plasia through to dysplasia, carcinoma in situ and,
ultimately, invasive carcinoma. Although the histo-
morphological changes in this process are recognized,
the underlying molecular alterations are only poorly
understood. Early alterations include overexpression of
cyclin D1, cyclin E and p53, whereas loss of retino-
blastoma expression occurs late in the development of
invasive carcinoma.
25 We found that although reduced
expression of MLH1, MSH2 and MGMT was not
uncommon in invasive NSCLC, it was relatively rare
in precursor lesions, with no reductions seen in the
earliest histological abnormalities of metaplasia and
dysplasia. Only very few cases of carcinoma in situ
showed reduced expression of the DNA repair proteins,
suggesting such alterations occur relatively late in the
pathogenesis of malignancy. Alternatively, the precur-
sor abnormalities studied could represent genetically
distinct lesions that had not given rise to the corre-
sponding invasive carcinoma present in the resected
specimen. However, the number of cases with precur-
sor squamous lesions was too low in our study to draw
a meaningful conclusion. Interestingly, reduced protein
expression was relatively uncommon in lymph node
metastasis, suggesting these alterations are unlikely to
play an important role in the development of metastatic
potential; however, the sample numbers with regional
node spread were small and a larger study would be
required to validate this ﬁnding.
Although reduced expression of DNA repair proteins
has been demonstrated in a variable proportion of
NSCLCs, the prognostic signiﬁcance of these alterations
has only very rarely been reported. In our study, we
have been unable to demonstrate any association
between alterations in expression of the DNA repair
proteins MLH1, MSH2 and MGMT and survival.
Similarly, in a study of non-smoking Taiwanese female
patients with NSCLC, neither MLH1 expression nor
promoter hypermethylation were signiﬁcantly associ-
ated with prognosis.
13 Although the authors were able
to demonstrate an association between MSH2 promoter
methylation and shorter overall survival, results of the
relationship between MSH2 protein expression and
survival were not reported.
13 Other studies examining
the methylation status of MLH1 and MGMT gene
promoters have not shown any correlation with overall
survival.
14 This is in contrast to colorectal carcinomas,
where defective MMR protein function is a beneﬁcial
prognostic feature.
1,26,27
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